Core Insights - 20/20 BioLabs, Inc. is an early market leader in AI-powered laboratory-based blood tests for early detection and prevention of cancers and chronic diseases [3][5] - The company will host a virtual investor webinar on February 26, 2026, to discuss its recent Nasdaq listing and product offerings [4][5] - The company offers two main products: OneTest™ for Cancer™, a multi-cancer early detection blood test, and OneTest for Longevity™, which measures inflammatory biomarkers [5][6] Company Overview - 20/20 BioLabs was listed on Nasdaq under the ticker symbol "AIDX" on February 19, 2026 [5] - The company operates a CAP-accredited and CLIA-licensed laboratory in Gaithersburg, MD, where tests are conducted [6] - The company also runs a Clinical Laboratory Innovation Accelerator (CLIAx) to support overseas diagnostics start-ups [7] Upcoming Initiatives - The OneTest for Longevity™ is expected to launch before the end of February 2026 [4] - The virtual investor webinar will include a question-and-answer session, allowing investors to engage directly with the company's leadership [4][5]

Core Insights - Oncotelic Therapeutics Inc. has been featured in an editorial by BioMedWire, highlighting its strategic positioning within the biotechnology sector [1][2] Industry Trends - Biotechnology mergers and acquisitions are increasingly focused on clinical-stage and late-stage programs that are backed by human data, moving away from early discovery platforms with uncertain timelines [2] - Investors are now prioritizing assets that show safety signals, efficacy data, and clearer pathways to commercialization, indicating a shift in investment strategies within the sector [2] Company Overview - Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing oncology and immunotherapy products, particularly targeting high-unmet-need cancers and rare pediatric indications [4] - The company has expanded its international intellectual property coverage for its proprietary TGF-β antisense therapeutic platform, OT-101, enhancing its protection across neurology, oncology, and CNS drug-delivery technologies [3] - Oncotelic holds a 45% stake in GMP Bio, a joint venture that is advancing its own pipeline of drug candidates, further strengthening Oncotelic's strategic position in oncology and rare disease therapeutics [4]

Core Viewpoint - Zelluna has received regulatory approval to initiate its first-in-human clinical trial for ZI-MA4-1, a TCR-NK cell therapy targeting solid cancers, marking a significant transition from preclinical to clinical-stage development [1][3][8]. Group 1: Clinical Trial Details - The ZIMA-101 trial will evaluate the safety, tolerability, and preliminary clinical activity of ZI-MA4-1 in patients with advanced solid cancers, including lung, ovarian, head and neck cancers, and sarcomas [3][4]. - The trial will be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust in Manchester, UK, with participation from Dr. Andrew Furness at The Royal Marsden in London, both recognized centers for oncology and early-phase cell therapy research [6][7]. Group 2: Product and Technology - ZI-MA4-1 is an off-the-shelf cell therapy that combines T cell receptors' precise targeting of solid tumors with the potent cancer-killing ability of Natural Killer cells, addressing limitations of existing therapies [4][10]. - The therapy specifically targets MAGE-A4, a protein present in various solid tumors, enhancing its potential effectiveness [4][10]. Group 3: Regulatory and Intellectual Property - The approvals from the MHRA and Ethics Committee signify a major milestone for Zelluna, reflecting the company's capabilities in science, manufacturing, and regulatory execution [4][5]. - Zelluna holds broad intellectual property coverage, including a significant patent that provides dominant protection over the TCR-NK field [5]. Group 4: Future Expectations - Initial clinical data from the ZIMA-101 trial is expected to emerge by mid-2026, providing insights into the broader potential of the TCR-NK platform [8][9].

Off The Hook YS Inc. Miami Supercenter Strategic move into physical global mega-destination site complements Off The Hook’s industry-leading AI-powered online marketplace, the largest of its kind for pre-owned boats in the U.S. Centralized hub to support the Company’s rapidly expanding inventory pipeline and international buyer network Wilmington, NC, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Off The Hook YS Inc. (NYSE American: OTH) (“Off The Hook Yachts” or “Off The Hook” or “the Company”), a vertically integ ...

Company Overview - Kirby Corporation has appointed Tracy A. Embree as a new independent member of its Board of Directors effective February 16, 2026, with her election to be held at the annual meeting in April 2026 [1] - Kirby Corporation is the largest domestic tank barge operator in the United States, transporting bulk liquid products across various waterways and coasts [5] Leadership Experience - Tracy A. Embree has over 25 years of global leadership experience in industrial operations, manufacturing, distribution, and services [2] - She previously served as President of Otis Americas, overseeing new equipment and service businesses across North and South America [3] - Embree has held senior leadership roles at Cummins Inc. for over two decades, focusing on power generation and overseeing global manufacturing and operational functions [3] Board Contributions - Embree's extensive experience in power generation and her leadership background are expected to enhance the expertise of Kirby's Board of Directors [2][5] - She currently serves as an independent director at Lennox International, Inc. and KLA Corporation, and has previously been an independent director at Louisiana-Pacific Corporation [4] Company Operations - Kirby Corporation transports a variety of products including petrochemicals, black oil, refined petroleum products, and agricultural chemicals [5] - The company also provides equipment, aftermarket parts, and services for power generation systems, and rents equipment for various industrial markets [5]

Core Viewpoint - Rio2 Limited is actively engaging in industry conferences to discuss growth plans for its Fenix Gold Mine and the newly acquired Condestable Mine, indicating a focus on expansion and investor relations [1][2]. Group 1: Company Overview - Rio2 Limited is a diversified producer of precious metals and copper, currently operating the Fenix Gold heap leach mine in Chile and the Condestable underground mine in Peru [3]. - The management team of Rio2 has a proven track record in technical skills and capital markets, emphasizing their capability in building and operating mines [3]. - The company is committed to high environmental standards and responsible development, aiming to exceed regulatory requirements to protect the environment [3]. Group 2: Upcoming Events - Rio2's executive team will present at BMO's 35th Global Metals, Mining, and Critical Minerals Conference on February 25, 2026, at 9:00 AM [1]. - The presentation will be available via webcast, allowing broader access to stakeholders [2]. - Additionally, Rio2 will participate in the PDAC, with a presentation scheduled for March 2 at 10:10 AM during Peru Day [2].

Core Insights - VCI Global Limited has launched ROBODAX, a strategic platform initiative aimed at integrating its robotics automation and real-world asset digital infrastructure strategies into a unified execution architecture [1][2][4] Group 1: ROBODAX Initiative - The formation of ROBODAX signifies a structural shift towards an AI-native infrastructure operating model, integrating robotics automation, AI orchestration, tokenization architecture, and enterprise settlement capabilities [2][4] - ROBODAX is designed to link physical automation outputs with digital asset infrastructure, supporting monetization models that connect robotics-generated activities with tokenized commerce [3][5] - Although ROBODAX is not currently a revenue-generating product, it is expected to enhance the company's long-term infrastructure positioning and operational efficiency [4][6] Group 2: Company Strategy and Operations - The company operates a platform-based model that allows subsidiaries and affiliates to connect with centralized AI, data, governance, and capital allocation systems, promoting faster execution and scalable growth [7][8] - VCI Global maintains a diversified exposure across various sectors, including advisory, AI, digital infrastructure, energy, automotive, and consumer sectors, continuously evaluating opportunities for growth and capital deployment [9]

Core Viewpoint - Digital Currency X Technology Inc. has regained compliance with Nasdaq's minimum bid price requirement, ensuring its continued listing on the Nasdaq Capital Market [1][2]. Group 1: Compliance and Listing Status - The company received a notification from Nasdaq confirming compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) [1]. - A previously scheduled hearing on February 24, 2026, has been canceled due to the company's regained compliance [2]. - The company's securities will continue to be listed and traded on the Nasdaq Capital Market without interruption [2]. Group 2: Company Overview - Digital Currency X Technology Inc. is a pioneering digital asset treasury management company focused on secure cryptocurrency custody and storage solutions [3]. - The company is positioned at the forefront of institutional digital asset adoption and is executing a comprehensive digital currency strategy [3]. - Key components of the company's strategy include treasury optimization, participation in decentralized finance (DeFi) ecosystems, and development of advanced custody infrastructure [3].

Financial Calendar - The financial calendar for 2026/2027 has been scheduled, detailing key reporting dates for the company [2] - The Annual Report for 2025 is set to be released on February 25, 2026 [2] - The Annual General Meeting for 2026 will take place on March 24, 2026 [2] - The Interim Report for the first half of 2026 is scheduled for August 26, 2026 [2] - The Annual Report for 2026 is planned for release on February 23, 2027 [2] - The Annual General Meeting for 2027 is set for March 18, 2027 [2]

Core Viewpoint - MARA Holdings, Inc. will hold a webcast and conference call to discuss its financial results for the quarter and fiscal year ended December 31, 2025, on February 26, 2026, at 5:00 p.m. Eastern time [1]. Group 1 - The financial results will be published in a shareholder letter prior to the call on the investor relations section of the Company's website [1]. - Participants can register for the conference call or listen to the live audio webcast through a provided link [2]. - The webcast will be available for replay via the investor relations section of the Company's website [2]. Group 2 - MARA Holdings, Inc. is a leading digital energy and infrastructure company that deploys digital energy technologies to advance global energy systems [4]. - The company transforms excess energy into digital capital, balancing the grid and accelerating the deployment of critical infrastructure [4]. - MARA develops technologies aimed at reducing the energy demands of high-performance computing applications, including AI [4].